Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 5:41 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 697–720 of 145,369 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Disorders Clear all

Conditions: HIV Diagnosis
Interventions: COPPEhR Intervention, Device-only Control Condition; Behavioral
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 50 Years and older
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: COVID-19
Interventions: Hydroxychloroquine (HCQ); Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Liver Cirrhosis
Interventions: Zibotentan; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Glendale, California

Conditions: Spinal Deformity, Spinal Degenerative Disorder, Spinal Fusion Failure, Spinal Trauma, Spinal Tumor Case
Interventions: Follow-up schedule: pre-operative baseline up to 24-months post-procedure; Device
Lead sponsor: Medtronic Spinal and Biologics; Industry
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2031
U.S. locations: 23
States / cities: Tucson, Arizona • Little Rock, Arkansas • Sacramento, California + 19 more

Conditions: Obstructive Sleep Apnea
Interventions: Inspire® UAS System; Device
Lead sponsor: Inspire Medical Systems, Inc.; Industry
Eligibility: 22 Years and older
Enrollment: 127 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2025
U.S. locations: 14
States / cities: Birmingham, Alabama • Los Angeles, California • Miami, Florida + 9 more

Conditions: Hemophilia A
Interventions: PEGylated Recombinant Factor VIII; Biological
Lead sponsor: Baxalta now part of Shire; Industry
Eligibility: 12 Years to 65 Years
Enrollment: 135 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 14
States / cities: Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 11 more

Conditions: Atrial Fibrillation, Arrhythmia, Stroke, Cardiovascular
Interventions: The Lifestar Act III; Device
Lead sponsor: University of Miami; Other
Eligibility: 40 Years to 85 Years
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Hereditary Angioedema
Interventions: NTLA-2002, Normal Saline IV Administration; Biological
Lead sponsor: Intellia Therapeutics; Industry
Eligibility: 16 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 14
States / cities: Scottsdale, Arizona • San Diego, California • Santa Monica, California + 11 more

Conditions: Lupus Nephritis - WHO Class III, Lupus Nephritis - WHO Class IV, Refractory Systemic Lupus Erythematosus, SLE
Interventions: AB-101, Cyclophosphamide, Fludarabine, Rituximab, Obinutuzumab; Drug
Lead sponsor: Artiva Biotherapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 9
States / cities: Birmingham, Alabama • Tucson, Arizona • San Diego, California + 6 more

Conditions: Multiple Sclerosis (MS) Secondary Progressive
Interventions: Dasatinib and quercetin; Drug
Lead sponsor: Ohio State University; Other
Eligibility: 50 Years to 85 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Knee Osteoarthritis, Osteo Arthritis Knee
Interventions: Microfragmented Adipose Tissue derived using the Lipogems® System, Saline Injection; Device · Drug
Lead sponsor: Lipogems International spa; Industry
Eligibility: 18 Years and older
Enrollment: 173 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 16
States / cities: Phoenix, Arizona • Encinitas, California • La Mesa, California + 13 more

Conditions: Healthy Volunteers
Interventions: NPT200-11, Placebo; Drug
Lead sponsor: Neuropore Therapies Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 55 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Neuroendocrine Tumor, Carcinoid Tumor, Pancreatic Neuroendocrine Tumor
Interventions: Sorafenib, RAD001; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Advanced Malignant Neoplasm, ALK Fusion Protein Expression, ALK Gene Amplification, ALK Gene Mutation, Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Neoplasm in the Central Nervous System, Metastatic Malignant Solid Neoplasm, ROS1 Fusion Positive, ROS1 Gene Amplification, ROS1 Gene Mutation
Interventions: Brigatinib, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Questionnaire Administration; Drug · Other
Lead sponsor: Sameek Roychowdhury; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Diabetes Mellitus, Type 2
Interventions: Diabetes mellitus Type 2 De-escalation treatment (DET); Drug
Lead sponsor: Sciema UG; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: HPV16 Positive, Cervical Intraepithelial Neoplasia (CIN 2/3)
Interventions: DNA vaccination, Gene gun vaccine, intramuscular vaccination, intra-lesional vaccine administration, therapeutic resection of the lesion, imiquimod; Biological · Device · Procedure + 1 more
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older · Female only
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2016
U.S. locations: 3
States / cities: Birmingham, Alabama • Baltimore, Maryland

Conditions: Critical Limb Ischemia
Interventions: care as usual; Other
Lead sponsor: Saint Luke's Health System; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 2
States / cities: New Haven, Connecticut • Cleveland, Ohio

Conditions: Breast Cancer Lymphedema
Interventions: Hand Mobility and Grip Strengthening Exercises, Usual Care; Other
Lead sponsor: Texas Woman's University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 3
States / cities: Albuquerque, New Mexico • Rio Rancho, New Mexico • Santa Fe, New Mexico

Conditions: Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
Interventions: Family-Directed Cognitive Adaptation Program; Behavioral
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2015
U.S. locations: 2
States / cities: Boston, Massachusetts • Jamaica Plain, Massachusetts

Conditions: Type 1 Diabetes, Hypoglycemia, Hyperglycaemia Due to Type 1 Diabetes Mellitus, Menstruation Disturbances
Interventions: Personalized modifications to treatment to address menstrual cycle effects on glycemia; Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Weight Loss
Interventions: RCT1, RCT2, RCT3; Behavioral
Lead sponsor: RTI International; Other
Eligibility: 18 Years to 64 Years
Enrollment: 2,395 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 3
States / cities: Swansea, Illinois • Research Triangle Park, North Carolina • Fairborn, Ohio

Conditions: Obstructive Sleep Apnea
Interventions: Encore Tongue Suspension System; Device
Lead sponsor: Siesta Medical, Inc.; Industry
Eligibility: 20 Years to 65 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: COVID-19, SARS-CoV 2
Interventions: Bicalutamide 150 Mg Oral Tablet; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Breast Cancer, Invasive Breast Cancer, Unresectable Breast Carcinoma, Locally Advanced Breast Cancer, Metastatic Breast Cancer, Inflammatory Breast Cancer, Triple Negative Breast Cancer (TNBC), Hormone Receptor/Growth Factor Receptor-Negative Breast Cancer, HER2-negative Breast Cancer, Hormone Receptor Negative Breast Carcinoma
Interventions: Onvansertib, Paclitaxel; Drug
Lead sponsor: Antonio Giordano, MD; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 3
States / cities: Boston, Massachusetts

Search by objective public record fields.

A Technology-based Psychosocial Intervention to Support Social Engagement and Well-being in Older Adults With HIV

COVID-19 PrEP HCW HCQ Study

A Study to Investigate the Blood Concentrations of 4 Different Oral Doses of Zibotentan in Healthy Non-Asian and Japanese Participants

The Ailliance Post-Market Clinical Study

Inspire® Post-Approval Study / Protocol Number 2014-001

BAX 855 PK-guided Dosing

Arrhythmia Detection In Obstructive Sleep Apnea (ADIOS)

HAELO: A Phase 3 Study to Evaluate NTLA-2002 in Participants With Hereditary Angioedema (HAE)

AB-101 in Combination With B-Cell Depleting mAb in Patients Who Failed Treatment for Class III or IV Lupus Nephritis or Other Forms of Refractory Systemic Lupus Erythematosus

Senolytics for Secondary Progressive MS

Microfragmented Adipose Tissue Compared to Saline Injection for the Treatment of Knee Osteoarthritis

Phase 1 Study of NPT200-11 in Healthy Subjects

Sorafenib in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors

Brigatinib in Treating Patients With ALK and ROS1 Gene Alterations and Locally Advanced or Metastatic Solid Cancers

Evaluation of the Impact of Intensive Short-Term Drug Therapy in Patients With Type 2 Diabetes Mellitus

Therapeutic Vaccination for Patients With HPV16+ Cervical Intraepithelial Neoplasia (CIN2/3)

SCOPE CLI (Shifting Care and Outcomes for Patients With Endangered Limbs - Critical Limb Ischemia)

The Effect of Hand Exercises on Upper Limb Volume, Quality of Life, and Hand Function in Breast Cancer Survivors

Family-Directed Cognitive Adaptation Program for Individuals With Schizophrenia

Impact of MEnstruation on Glycemic Response and Exercise In Females With Type 1 Diabetes

Weight Management Demonstration Project: HEALTH

FAST as a Treatment for Obstructive Sleep Apnea

Trial to Promote Recovery From COVID-19 With Endocrine Therapy

Onvansertib + Paclitaxel In TNBC